Cardiol Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRDL.TO research report →
Price Chart
About the company
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial.
- CEO
- David G. Elsley
- IPO
- 2018
- Employees
- 18
- HQ
- Oakville, ON, CA
Get TickerSpark's AI analysis on CRDL.TO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $300.86M
- P/E
- -7.59
- Fwd P/E
- 16.66
- PEG
- -0.21
- P/S
- 0.00
- P/B
- 12.48
- EV/EBITDA
- -7.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -180.13%
- ROIC
- -148.56%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-101,983+72.7%
- Op Income
- $-34,316,296
- Net Income
- $-33,818,874+7.8%
- EPS
- $-0.39+23.5%
- OCF Growth
- +4.8%
- FCF Growth
- +4.8%
- 52W High
- $2.75
- 52W Low
- $1.23
- 50D MA
- $1.73
- 200D MA
- $1.59
- Beta
- 0.47
- RSI (14)
- 78
- Avg Volume
- 99.85K
No earnings-call transcripts are available for CRDL.TO yet.
- Free Float
- 83.7%
- Shares Outstanding
- 115.27M
- Float Shares
- 96.50M
Held by 1 ETFs
Biggest fund positions in CRDL.TO by dollar value.
Our CRDL.TO coverage
Recent articles, reports, and earnings notes.
No research on CRDL.TO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRDL.TO report →Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – Time to Sell?
defenseworld.net · Feb 6
Cardiol Therapeutics (TSE:CRDL) Shares Down 7.1% – What’s Next?
defenseworld.net · Feb 6
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.5% – What’s Next?
defenseworld.net · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.